New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2013
07:22 EDTRHHBY, GGG, CA, IOSP, GE, ASML, VLO, GWW, CHMT, AYIOppenheimer to host a conference
3rd Annual Investor 1-on-1 Conference is being held in London, England on February 6.
News For AYI;ASML;CA;CHMT;GE;GGG;GWW;IOSP;RHHBY;VLO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 15, 2015
06:01 EDTVLOValero remains a top pick at Goldman
Subscribe for More Information
May 14, 2015
10:09 EDTGWWIncreasing equity options volume on open
Increasing equity options volume on open: ONTY CBRL PBYI GWW AXLL IEV KSS EXPR UEC JACK
09:38 EDTGWWIncreasing equity options volume on open
Subscribe for More Information
09:22 EDTRHHBYLeerink pharma/biotech analysts hold an analyst/industry conference call
Subscribe for More Information
May 13, 2015
18:12 EDTRHHBYGenentech alectinib shrank tumors in about half of ALK-positive NSCLC patients
Subscribe for More Information
17:04 EDTRHHBYGenentech announces interim results from POPLAR study
Genentech, a member of the Roche Group announced interim results from a global, randomized Phase II study, POPLAR, in people with previously treated non-small cell lung cancer, NSCLC. The study showed the investigational cancer immunotherapy MPDL3280A doubled the likelihood of survival; hazard ratio [HR]=0.47) in people whose cancer expressed the highest levels of PD-L1 compared with docetaxel chemotherapy. An improvement in survival was also observed in people who had medium and high or any level of PD-L1 expression, as characterized by a test being developed by Roche. MPDL3280A was generally well tolerated and adverse events were consistent with what has been previously reported for MPDL3280A in NSCLC. Updated results will be presented in an oral session at the 51st Annual Meeting of the American Society of Clinical Oncology. “In our study of MPDL3280A in previously treated lung cancer, the amount of PD-L1 expressed by a person’s cancer correlated with improvement in survival,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The goal of PD-L1 as a biomarker is to identify people most likely to experience improved overall survival with MPDL3280A alone, and which people may be appropriate candidates for a combination of medicines.”
11:17 EDTGEGE looks to sell Japan commercial finance operation, WSJ says
General Electric is looking to sell its Japanese commercial finance operations, as the conglomerate looks to slim down assets held in its GE Capital unit, says the Wall Street Journal. The unit, which finances the purchase of equipment is valued at about $5B, added the Wall Street Journal. Reference Link
09:39 EDTGEActive equity options trading on open
Subscribe for More Information
08:01 EDTGWWGrainger reports April sales up 1%
Subscribe for More Information
07:08 EDTGEOppenheimer to hold a conference
Subscribe for More Information
06:50 EDTAYIAcuity Brands price target raised to $207 from $194 at Piper Jaffray
Piper Jaffray raised its price target for Acuity Brands to $207 saying its seeing "positive and steady" improvement in several lighting end markets. Piper expects further market share gains to drive shares higher and keeps an Overweight rating on Acuity.
06:15 EDTGEEU restart probe of GE's planned acquisition of Alstom's power business, WSJ say
Subscribe for More Information
May 12, 2015
10:45 EDTGEAnalyst says Pall deal may spark more life sciences M&A
Subscribe for More Information
09:51 EDTGEPall Corp. could be precursor to more Life Science deals, says Janney Capital
After The Wall Street Journal said Pall Corp. (PLL) is nearing a possible sale, naming Thermo Fisher (THO) and Danaher (DHR) as potential suitors, Janney Capital said it thinks dealmaking in the Life Sciences space won't stop with Pall, listing Repligen (RGEN), Bio-Techne (TECH) and VWR (VWR) as others in the industry that could see strategic bids emerge. The firm added that it expects that GE (GE), 3M (MMM), and private equity firms would also be involved in bidding in deals in the space.
07:37 EDTGGGOppenheimer to hold a conference
10th Annual Industrial Growth Conference is being held in New York on May 12-13 with webcasted company presentations to begin on May 12 at 8:15 am; not all company presentations may be webcasted. Webcast Link
May 11, 2015
17:23 EDTGEGE would consider concessions to secure Alstom deal, Reuters says
Subscribe for More Information
12:35 EDTGEGE not likely to gain unconditional approval for Alstom deal, Reuters reports
Subscribe for More Information
12:28 EDTGEGE launches cloud foundry ‘Industrial Dojo’
GE Software announced its ‘Industrial Dojo,’ in collaboration with the Cloud Foundry Foundation, to strengthen its efforts to solve the world’s biggest industrial challenges. The Cloud Foundry Dojo program allows software developers to immerse themselves in open source projects to quickly learn the inner workings of the core technology and the unique agile development environment, as well as recommended methodologies for contributing code. GE also announced it will work with the Cloud Foundry community to develop and contribute open source code to the Cloud Foundry Foundation that will route all industrial messaging protocols. By opening this Industrial Dojo, GE Software is enabling developers to better learn industrial intricacies by pairing with experienced developers, thereby greatly reducing the time-to-productivity for those new to a project. Through this program, GE is bolstering its commitment to open source development and Cloud Foundry, and ultimately promoting the next wave of industrial innovation. Also announced, GE will drive, in collaboration with Pivotal, creation of a “TCP Router” to direct non-HTTP protocols and better equip Cloud Foundry to connect industrial machines with IT networks. By donating this innovation to the open source community, GE will enable Cloud Foundry to be used in a variety of industrial applications and use cases.
10:21 EDTGEGE says EU suspends review on Alstom deal, sees probe resuming, Reuters reports
General Electric (GE) said the investigation of its takeover bid for Alstom's (ALSMY) power equipment business was suspended last month by EU antitrust regulators, Reuters reports. GE says the probe was halted on April 24 to give the regulators time to review additional information, and believes the review will restart this week. Reference Link
05:11 EDTRHHBYRoche receives FDA approval for cobas KRAS Mutation Test
Roche announced that the FDA has approved the cobas KRAS Mutation Test for diagnostic use. The real-time PCR test is designed to identify KRAS mutations in tumor samples from metastatic colorectal cancer, or mCRC, patients and aid clinicians in determining a therapeutic path for them.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use